Granulocyte Colony-Stimulating Factor (G-CSF) Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Filgrastim, G-CSF, Granix, Neupogen, Pegfilgrastim +1 more

Pipeline

Phase 2: 1Phase 4: 1Phase 2/3: 1

Top Sponsors

Ottawa Hospital Research Institute1
Merck Sharp & Dohme LLC1
Massachusetts General Hospital1

Indications

Cancer3
Newly Diagnosed Glioblastoma Multiforme1
MGMT-Methylated Glioblastoma1
Glioblastoma (GBM)1
DLBCL1

Other1 trial

Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy

Phase 4

Glendale, Arizona1 trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

Phase 2/3

Boston, Massachusetts1 trial

G-CSF After Chemo-radiation in Patients With Glioblastoma

Massachusetts General Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.